Jubilant Pharmova Limited (NSE:JUBLPHARMA)

Market Cap	149.42B -12.6%
Revenue (ttm)	86.08B +16.3%
Net Income	3.52B -23.5%
EPS	22.17 -23.5%
Shares Out	n/a
PE Ratio	42.14
Forward PE	27.61
Dividend	5.00 (0.53%)
Ex-Dividend Date	Jul 24, 2026

Volume	80,732
Open	931.60
Previous Close	938.60
Day's Range	931.50 - 948.40
52-Week Range	786.05 - 1,184.80
Beta	0.47
Analysts	Hold
Price Target	1,088.50 (+15.49%)
Earnings Date	Oct 30, 2026

About Jubilant Pharmova

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of pulmonary embolism, cancer, coronary artery disease, and other di...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 5,657
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: JUBLPHARMA

Financial Performance

In fiscal year 2026, Jubilant Pharmova's revenue was 82.80 billion, an increase of 14.45% compared to the previous year's 72.35 billion. Earnings were 3.99 billion, a decrease of -52.53%.

Analyst Summary

According to 2 analysts, the average rating for JUBLPHARMA stock is "Hold." The 12-month stock price target is ₹1,089, which is an increase of 15.49% from the latest price.

Price Target

₹1,089

(15.49% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 20, 2026

Data Sources Report a data error